207 related articles for article (PubMed ID: 36309653)
21. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Mitry E; Ducreux M; Rougier P
Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
[TBL] [Abstract][Full Text] [Related]
22. [Irinotecan in combination for colon cancer].
Ducreux M; Gil-Delgado M; André T; Ychou M; de Gramond A; Khayat D
Bull Cancer; 1998 Dec; Spec No():43-6. PubMed ID: 9932084
[TBL] [Abstract][Full Text] [Related]
23. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
24. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
Atreya CE; Ducker GS; Feldman ME; Bergsland EK; Warren RS; Shokat KM
Invest New Drugs; 2012 Dec; 30(6):2219-25. PubMed ID: 22270257
[TBL] [Abstract][Full Text] [Related]
25. ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.
Subhash VV; Tan SH; Yeo MS; Yan FL; Peethala PC; Liem N; Krishnan V; Yong WP
Mol Cancer Ther; 2016 Dec; 15(12):3087-3096. PubMed ID: 27638859
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Shelton JW; Waxweiler TV; Landry J; Gao H; Xu Y; Wang L; El-Rayes B; Shu HK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):469-76. PubMed ID: 23540347
[TBL] [Abstract][Full Text] [Related]
27. XRCC2-Deficient Cells are Highly Sensitive to 5-Fluorouracil in Colorectal Cancer.
Zhang YZ; An JH; Liu YX; Wu XC; Han SS; Ren XQ; Qin CJ
Cell Physiol Biochem; 2017; 43(3):1207-1219. PubMed ID: 28977800
[TBL] [Abstract][Full Text] [Related]
28. Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells.
Huang CI; Huang YK; Lee HM; Chen JH; Su YC; Lin PM
Anticancer Res; 2023 May; 43(5):1933-1941. PubMed ID: 37097665
[TBL] [Abstract][Full Text] [Related]
29. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
31. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
32. The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.
Greene J; Nguyen A; Bagby SM; Jones GN; Tai WM; Quackenbush KS; Schreiber A; Messersmith WA; Devaraj KM; Blatchford P; Eckhardt SG; Cadogan EB; Hughes GD; Smith A; Pitts TM; Arcaroli JJ
Oncotarget; 2017 Dec; 8(67):110904-110913. PubMed ID: 29340025
[TBL] [Abstract][Full Text] [Related]
33. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Martinez-Balibrea E; Abad A; Martínez-Cardús A; Ginés A; Valladares M; Navarro M; Aranda E; Marcuello E; Benavides M; Massutí B; Carrato A; Layos L; Manzano JL; Moreno V
Br J Cancer; 2010 Aug; 103(4):581-9. PubMed ID: 20628391
[TBL] [Abstract][Full Text] [Related]
34. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
35. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Clarke SJ; Yip S; Brown C; van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ;
Eur J Cancer; 2011 Aug; 47(12):1826-36. PubMed ID: 21665462
[TBL] [Abstract][Full Text] [Related]
36. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
[TBL] [Abstract][Full Text] [Related]
37. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
38. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer.
Wu CW; Dong YJ; Liang QY; He XQ; Ng SS; Chan FK; Sung JJ; Yu J
PLoS One; 2013; 8(2):e57036. PubMed ID: 23437304
[TBL] [Abstract][Full Text] [Related]
40. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]